Yesterday, April 29, 2016, 41 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $10.00 to $137,337,930.00. Highlighted Stocks Traded by Insiders: Bank of the Ozarks (OZRK) - FREE Research Report Koefoed William A, who is Director at Bank of the Ozarks, bought 1,000 shares at $41.78 on April 29, 2016. Following this transaction, the Director owned 1,589 shares meaning that the stake was boosted by 169.78% with the 1,000-share transaction. The shares most recently traded at $41.30, down $0.48, or 1.17% since the insider transaction. Historical insider transactions for Bank of the Ozarks go as follows:

  • 4-Week # shares bought: 4,450
  • 4-Week # shares sold: 9,589
  • 12-Week # shares bought: 4,450
  • 12-Week # shares sold: 9,589
  • 24-Week # shares bought: 4,500
  • 24-Week # shares sold: 9,589

The average volume for Bank of the Ozarks has been 1.3 million shares per day over the past 30 days. Bank of the Ozarks has a market cap of $3.9 billion and is part of the financial sector and banking industry. Shares are down 15.51% year-to-date as of the close of trading on Thursday. Bank of the Ozarks, Inc. operates as a bank holding company for Bank of the Ozarks that provides various banking products and services. The stock currently has a dividend yield of 1.43%. The company has a P/E ratio of 20.7. Currently, there is 1 analyst who rates Bank of the Ozarks a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OZRK - FREE

TheStreet Quant Ratings

rates Bank of the Ozarks as a

buy

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, notable return on equity and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Bank of the Ozarks Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Century Bancorp (CNBKA) - FREE Research Report

Filler James J, who is 10% Owner at Century Bancorp, bought 500 shares at $42.40 on April 29, 2016. Following this transaction, the 10% Owner owned 506,142 shares meaning that the stake was boosted by 0.1% with the 500-share transaction. The shares most recently traded at $42.88, up $0.48, or 1.12% since the insider transaction. Historical insider transactions for Century Bancorp go as follows:

  • 4-Week # shares bought: 5,045
  • 12-Week # shares bought: 5,812
  • 24-Week # shares bought: 31,414

The average volume for Century Bancorp has been 4,000 shares per day over the past 30 days. Century Bancorp has a market cap of $240.6 million and is part of the financial sector and banking industry. Shares are down 0.55% year-to-date as of the close of trading on Thursday. Century Bancorp, Inc. operates as a bank holding company for Century Bank and Trust Company that provides banking products and services. It accepts savings accounts, NOW accounts, demand deposits, time deposits, and money market accounts, as well as cash management accounts. The stock currently has a dividend yield of 1.11%. The company has a P/E ratio of 8.5.

Exclusive Offer: Get the latest Stock Analysis on CNBKA - FREE

TheStreet Quant Ratings

rates Century Bancorp as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share and increase in net income. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full

Century Bancorp Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Anacor Pharmaceuticals (ANAC) - FREE Research Report

Sullivan Ryan T, who is EVP and General Counsel at Anacor Pharmaceuticals, sold 3,125 shares at $66.33 on April 29, 2016. Following this transaction, the EVP and General Counsel owned 30,132 shares meaning that the stake was reduced by 9.4% with the 3,125-share transaction. The shares most recently traded at $62.74, down $3.59, or 5.72% since the insider transaction. Historical insider transactions for Anacor Pharmaceuticals go as follows:

  • 4-Week # shares sold: 37,500
  • 12-Week # shares sold: 46,500
  • 24-Week # shares sold: 92,087

The average volume for Anacor Pharmaceuticals has been 1.1 million shares per day over the past 30 days. Anacor Pharmaceuticals has a market cap of $3.0 billion and is part of the health care sector and drugs industry. Shares are down 41.35% year-to-date as of the close of trading on Thursday. Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It markets KERYDIN (tavaborole) topical solution for the treatment of onychomycosis of the toenails. Currently, there are 3 analysts who rate Anacor Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ANAC - FREE

TheStreet Quant Ratings

rates Anacor Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, disappointing return on equity and generally high debt management risk. Get the full

Anacor Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.